Archive for the ‘Male Genetics’ Category

Males, who have long been branded as the dominant gender in our species, have been undervalued since Eve turned Adam in to a hapless co-conspirator in the downfall of humanity.

We have a reputation of being driven by our animal passions and prejudices. Females get the credit for compassion and reason. With few exceptions in history, wars have not been started by women in power.

America has changed dramatically in its view of fatherhood and the responsibility the title entails. The one thing that remains constant in our society, and among our species, is that the young need direction, training, leadership and nurturing from a parent to thrive and sometimes even to survive.

Sadly, we are all products of our upbringing no matter how hard we try to remake ourselves as age and reason overtake us. My mother, God bless her, was a product of a five-sister home in the 30s. Getting out and getting a husband was vital. A man in her life was a life-long priority.

She had five husbands and a few other long-term relationships over her long life. I had three half-siblings fathered by her first husband. Then I came along with husband two after World War II. In a sense, I consider myself lucky because as I grew up, I had several choices of male role models. Some were winners, some were not. I got the genetics of being a big, garrulous hard drinker from my Irish birth father who drifted in and out of my life until he died after a drunken fall at age 47.

Sensing my needs, Mother then found a genial, well-known fellow who was the pillar of the community to take us in. It is his name, Orr, that I adopted when I came of age because it became clear to me even then that there are sperm donors and there are fathers. Do not confuse one with the other. Fathers contribute. They stay. They help. They teach and lead by example.

Ray Orr was a cop. He and his family of two older brothers were icons in Ontario for their contributions to youth sports. I was immediately accepted as a "good guy" when I entered high school simply trading on the goodwill of my new last name. It was an unimaginable gift. Acceptance, belonging and mentoring all in one fell swoop.

Ray also gave me one sage piece of advice that helped me keep on the straight and narrow through high school and college, an era of "free love" and doobies. He sat me down and said, "Pat, dont ever call me from jail because no one is coming. You are responsible for your actions."

That is fatherhood in my view.

I had another cop involved throughout my life that taught me about responsibility and hard work. My mom worked for the LAPD at the old Georgia Street Jail in the early 1950s and became friends with a sergeant named Lloyd Lindsey. He was a go-getter.

He and his wife had a third child and needed extra cash. He chose to take his vacation and work at a food stand at the Los Angeles County Fair owned by a fellow cop. Lloyd was so intrigued by the food business that he borrowed some money and opened his own food stand the following year.

To work there he recruited people he knew that could be fast and honest. He asked my mom to work weekends. She was between husbands and brought me along. I cleaned tables and Lloyd gave me a quarter a day. I worked for him on and off all the way through high school and during college breaks. I learned a great deal about customer service and marketing your product. He always gave me more responsibility when he knew I was ready.

Years later, I married his daughter and Lloyd encouraged and mentored us in our first food concession business. That turned into his helping us investigate a fast food franchise opportunity, which led us to become a multi-store operator in the High Desert.

Lloyd Lindsey taught me to work hard, to live your dream and to not to be afraid of taking a chance on yourself. That is being a father.

Right now, you are hearing a lot about "systemic racism" in America. It would be nice to have an honest conversation about the state of fatherhood in the African American community. About 70% of African American children are born out of wedlock, while married couples of color are having fewer children than ever.

Unfortunately, it seems to me that well-intentioned liberals have designed a welfare system that punishes women who choose to get married to the father to their child. The rise in illegitimate births affects all races in America, but it is particularly apparent in the African American community.

Children from two-parent families are more likely to finish high school and get some college, less likely to commit a crime or go to prison and more likely to become productive hard-working contributing members of the community in which they choose to live. Why is it so hard to redirect some of the billions we have spent over the last 60 years on social programs for the poor to family building, which is proven to break the poverty cycle?

Is it a coincidence that prior to 1965, when the "War on Poverty" swung into full gear, the social stigma against unwed mothers resulted in most pregnant couples getting married? In the 1960s and 1970s, the culture changed. Moral values changed and unwed pregnancies began to skyrocket. Benefits for dependent children were created.

There is no question that money is a major consideration to the rise of illegitimate births. It is less expensive to cohabitate than marry. The marriage commitment also binds people legally to be responsible for minor children. Commitment to anything but self has become less popular in our culture as the decades have passed. Abortion is a normal option now for unwanted pregnancy, which makes irresponsible sexual activity by men and women an accepted norm.

Why does marriage make a difference? Studies indicate that there is a 39% chance of the family breaking apart if the parents are not married. That number plummets to just 13% for married couples. Figures can be manipulated, but the clear relationship between fatherless homes, poverty, crime and poor life skills is all too evident in our major cities. The poorest city in America, Washington D.C., also has the highest rate of out-of-wedlock births. Coincidence? This cycle must be broken to achieve real racial equality.

On this day, when we celebrate fatherhood, we must ask ourselves if we have the courage to stand up and recognize that part of the reason for the disparity in the progress of minority children is the absence of two parents.

When do we return to the social and moral pressure in every community to get fathers to simply show up and be a father? How do we help that happen?

This does not mean that a white picket fence and minivan are the goals for every relationship. It means we should help young girls and women demand the self-respect of a commitment from any man with whom they partner marriage or no marriage.

Just find ways to encourage every father of every race to stand up and show up. Be a father for the future of your children, if not for yourself. That would be a great Fathers Day gift for America.

Contact Pat Orr at AVReviewOpinion@gmail.com.

Read more:
Around Town: Fathers matter - VVdailypress.com

While the attention of the American public has rightfully been focused on the COVID-19 pandemic, its associated racial disparities, and broader issues of structural racism, the US government made a serious public health decision one that could affect our health and our environment for generations to come.

Last month, the US Environmental Protection Agency approved the release of genetically modified mosquitoes. Under a 2-year Experimental Use Permit, a company called Oxitec has been granted permission to release over 1 billion genetically modified mosquitoes across 6,600 acres in Florida and Texas.

Oxitec hopes to demonstrate through field trials that their latest GM mosquito strain can reduce local populations of Aedes aegypti the mosquito species that transmits dengue fever, yellow fever, chikungunya, and the Zika virus. When males of this GM mosquito strain (OX5034) are continually released to mate in the wild, they pass on a lethal gene to their female offspring that causes female larvae to die before they can develop into biting adults. Male mosquito offspring survive, but male mosquitoes dont bite and without viable females, the population should eventually collapse.

EPA approval of the release of this new GM mosquito is just the first step toward Oxitec selling its proprietary mosquito to US mosquito-control boards, and by extension US taxpayers. Oxitec intends to deploy its GM mosquitoes in and around the Florida Keys and near Houston. If the appropriate local authorities agree, millions of GM mosquitoes could be released into the wild every week starting this summer.

With our combined scientific and policy expertise, neither of us is anti-genetically modified organisms. We eat GM foods and believe that GM technologies can have significant benefits to public health but only if they are used safely and fairly. The environmental introduction of the first GM mosquito in the United States is a landmark decision. Its public health, ecosystem, and societal risks and benefits should be carefully weighed.

In a recent press release, Oxitec claims its strategy is a safe and environmentally sustainable way to control mosquitoes that transmit disease. Yet the EPA did not convene an independent, external scientific advisory panel to review Oxitecs claim; the agencys risk assessment was only made publicly available after their approval decision and we know of no peer-reviewed articles on this particular GM mosquito strain.

Meanwhile, GM mosquitoes are being introduced into uncontained, shared environments that people live in and depend on. The EPA recently held a written public comment process that yielded over 31,000 comments where some worried the impacts of GM mosquito suppression could threaten food webs and strain already vulnerable ecosystems. Others feared GM mosquitoes, or their genetic material, could integrate into the wild; GM-wild hybrid mosquitoes could prove more difficult to control or better at spreading disease. (Several years ago, public meetings and a nonbinding referendum took place in Florida over a different Oxitec mosquito strain. Residents of Key Haven, the site of proposed trials, voted against the release.)

Oxitec has trialed their second generation GM mosquito in Brazil and succeeded in reducing local populations of Aedes aegypti. Given Brazils high mosquito-borne disease burden the country reported over 1.5 million probable cases of dengue fever in 2016 the potential benefits of GM mosquitoes may outweigh their unknown ecological risks. Yet in the United States, dengue outbreaks are relatively rare, yellow fever has been eradicated domestically, and 231 of documented Zika virus cases were caused by local mosquito transmissions, as opposed to those associated with travel. It is unclear whether the potential benefits of release in the United States (one could be chemical pesticide reductions) will outweigh the risks. These tradeoffs must be weighed in a public setting.

And herein lies our concern: Risks should not be assessed behind closed doors between technology developers and EPA employees. As designed, the EPA risk assessment process privileges private entities over the American public.

Several recommendations could be implemented to make the regulatory process more open, rigorous, and fair.

For starters, an external independent group of experts should be convened to review the first GM mosquitoes presented for release. To address the complexity of such a decision, this group should consist of interdisciplinary experts representing diverse identities with expertise in ecology, genetics, vector biology, risk assessment, entomology, public health, ethics, and social science. External peer review is a cornerstone of good science and could ensure that all necessary risks are being addressed.

To ensure rigorous review, the EPA and other regulatory bodies must also fund independent third-party research on GM mosquitoes and their potential impact on US ecosystems and human health. Potential risks are too important to be left to corporations alone to research, and the American public needs to be assured that these decisions are made free of conflicts of interest.

Lastly, and perhaps most important, people who live in areas of release must be consulted for their specialized, on-the-ground knowledge and for their right to have input in decisions that will affect them. Last week, the Florida Department of Agriculture and Consumer Services approved the EPA permit for experimental release. Oxitec must now get approval from the Florida Keys Mosquito Control Board. An independent group should host public conversations through local community venues, and it must make sure that structurally marginalized perspectives are at the center of those gatherings. But local community input should be consulted at every stage of the regulatory process, not after permits have already been granted. And earmarked government funding should support these local deliberations, as well as measures to amplify underrepresented perspectives in environmental regulation and biotechnology.

GMOs made with even more powerful genetic technologies like CRISPR gene editing and gene-drives are being created in the laboratory and considered for open-environmental release. The public needs to know that the risks and benefits of these decisions will likely impact us all, and certain communities even more so. The COVID-19 pandemic has made it clear that robust public health depends on informed communities who participate in collective actions. Release of GM mosquitoes is no different. For the health of ourselves, the nation, our planet, and future generations, environmental regulation of GMOs must be made more rigorous and just.

Natalie Kofler is founder of Editing Nature and an adviser for the Scientific Citizenship Initiative at Harvard Medical School. Jennifer Kuzma is a professor in the School of Public and International Affairs and co-director of the Genetic Engineering and Society Center.

The rest is here:
Before genetically modified mosquitoes are released, we need a better EPA - The Boston Globe

A clinical trial of hydroxychloroquine for the treatment of hospitalized adults with COVID-19 has been halted after the drug was found to be ineffective, the National Institutes of Health (NIH) announced on Friday.

According to the NIH's press release, the drug poses "no harm" to those who have taken it, but has still been deemed "very unlikely to be beneficial" to those being treated for coronavirus.

The study aimed to enroll "more than 500 adults who are currently hospitalized with COVID-19," and had enrolled more than 470 patients before it was halted, according to the NIH.

Advertisement

Though hydroxychloroquine is typically used to treat malaria and rheumatoid conditions like arthritis, according to the NIH, it had been tested to treat COVID-19 because "the drug had demonstrated antiviral activity, an ability to modify the activity of the immune system."

In recent months, hydroxychloroquine has been provided to a wide range of people across the US including 1,300 veterans infected with COVID-19.

"I take it," he said at the time. "I would've told you that three, four days ago, but we never had a chance because you never asked me the question."

More recently at the start of June, White House physician Sean Conley confirmed in a memo that Trump had been prescribed hydroxychloroquine, zinc, and vitamin D, for a two-week period. The note also stated that Trump "remains healthy" with "no findings of significance or changes to report" from his annual physical, as Business Insider's Grace Panetta previously reported.

See the rest here:
A clinical trial of hydroxychloroquine has been halted after the drug was deemed 'very unlikely to be benefici - Business Insider India

This is a Siamese fighting fish.

Betta fish opponents undergo similar brain changes that become more synchronized after longer fights.

When two betta fish are fighting for dominance, not only do their attacks mirror each other, but the gene expression in their brain cells also starts to align. The new findings, published June 17th in PLOS Genetics by Norihiro Okada of Kitasato University, Japan, may explain how the fish synchronize their fighting behavior.

The fighting fish Betta splendens is famous for its aggression, but opponents typically stop fighting after assessing the others abilities to avoid any serious injuries. The small freshwater fish is commonly used to study aggression in the lab, and it employs a handful of standard tactics like mouth-locking, bites, strikes, and swimming to the surface to gulp air. In the new study, researchers observed that during a fight, two male opponents modify their actions to match the aggressive behavior of the other, leading to tightly synchronized battles.

Furthermore, when the researchers analyzed the brains of both opponents, they observed that the fish also synchronized which genes were turned on or off in brain cells. The fighting pair had similar changes in gene activity related to learning, memory, synapse function and ion transport across cell membranes. The synchronization was specific to a fighting pair and became stronger after fighting for an hour compared to a 20-minute fight, suggesting that the degree of synchronization was driven by fighting interactions.

The new study takes a neurogenomic approach to the old question of how animals synchronize their behavior. Similar mirrored behaviors also occur during mating, foraging and cooperative hunting, and these behaviors may also trigger synchronized brain changes in the pairs of animals. One of my future plans is to elucidate what happens in the male-female interaction of fish on the molecular level, said author Norihiro Okada.

The findings suggest that even though the betta fish are fighting each other, sometimes to the death, their brains may be cooperating at the molecular level.

Reference: Behavioral and brain- transcriptomic synchronization between the two opponents of a fighting pair of the fish Betta splendens by Trieu-Duc Vu, Yuki Iwasaki, Shuji Shigenobu, Akiko Maruko, Kenshiro Oshima, Erica Iioka, Chao-Li Huang, Takashi Abe, Satoshi Tamaki, Yi-Wen Lin, Chih-Kuan Chen, Mei-Yeh Lu, Masaru Hojo, Hao-Ven Wang, Shun-Fen Tzeng, Hao-Jen Huang, Akio Kanai, Takashi Gojobori, Tzen-Yuh Chiang, H. Sunny Sun, Wen-Hsiung Li and Norihiro Okada, 17 June 2020, PLOS Genetics.DOI: 10.1371/journal.pgen.1008831

See original here:
Fighting Fish Synchronize Their Combat Moves and Gene Expression Leading to Tightly Meshed Battles - SciTechDaily

In an interaction with ETHealthworld, Preetha Reddy, Vice Chairperson, Apollo Hospitals and President, NATHEALTH, discusses the need to prioritize healthcare by collaborative approach.

As the new president of NATHEALTH, what will be your key priorities in the coming months?Over the course of the next few months, our priorities will be to continue our work towards bringing everyone in the healthcare ecosystem, to a unified platform through integration, collaboration and re-imagination. The road ahead for NATHEALTH is to be a competency centre par excellence for public-private partnerships, nurturing the innovation ecosystem in healthcare and driving new programs to bring in Government support and expanding our aperture. With this vision in mind, NATHEALTH will focus its efforts to bring together all the stakeholders and build the national health agenda.

How important is the need for Government and the private sector engagement in the present times? How is NATHEALTH going to take this forward?The path to achieve a holistic goal of universal healthcare, hinges on collaboration where all the key industry stakeholders come together, deliberate, cooperate and work in tandem to bridge the vital gaps in service delivery. An equally important task is to establish a collaborative platform to coordinate national resilience in the present times, through value based public private partnerships.

As a unified ecosystem, we will sharpen our focus on thought leadership, create new markets and tech access, robust communication, transparency in governance and forge partnerships with smaller organizations and nursing associations, to take this movement forward.

What is urgently needed to revamp Indian healthcare today, in your opinion?It is essential to rebuild trust among key stakeholders, work towards making universal health coverage a fundamental right and creating value for healthcare services. We will make continued efforts to help people understand the valuable contributions that the private health sector makes in handling critical cases and saving countless lives. We need to establish a win-win proposition by fostering partnership models which address healthcare gaps and driving a dialogue that is based on mutual respect and capabilities.

What are the recommendations from NATHEALTH towards collaborative initiatives to address the impact of COVID 19? The healthcare sector is currently tackling the twin challenges of lower productivity due to systemic shock to earnings and major cash flow challenges at a time when COVID-19 needs the entire sector to be motivated and secured as a united front. We believe that the public and private sectors will need to work in partnership to ensure existing challenges are managed better in future and universal health coverage becomes a reality.

This pandemic has made us realize that as stakeholders, the hospitals, med-tech companies, pharma, IT, the medical academia and nursing councils have to join hands, chalk out a plan and work towards it collectively. Collaboration is the way forward.

There is also a need to lay the foundation for building the infrastructure and financial capability with an immediate action plan to tackle such large public health emergencies, now and in the future.

In view of the several challenges facing the private healthcare industry, how does NATHEALTH plan on addressing these issues?Our plan is to actively engage with our four key stakeholder groups: Policymakers, Partners, People and Members to encourage a collaborative approach in addressing these issues. We will work with policymakers to shape industry policies and forge new partnerships with State Governments. We plan to expand our membership base to new markets over the upcoming months to enable smaller and medium healthcare providers to become part of the federations ecosystem, and identify new operating models, technology and knowledge through our members.

Overall, I believe, in order to work towards sustainable healthcare, we have to look at increased public-private partnerships and look at ways to bring the Government, academia and industry together. It is important for us as a nation to prioritize healthcare, bring in increased health investments, scale up medical education and leverage technology to establish much more health infrastructure.

Go here to read the rest:
We need to establish a win-win proposition by fostering partnership models to address healthcare gaps : Pree.. - ETHealthworld.com

This research report based on Male Breast Cancer Treatment market and available with Market Study Report, LLC, includes latest and upcoming industry trends in addition to the global spectrum of the Male Breast Cancer Treatment market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Male Breast Cancer Treatment industry.

Male breast cancer (male breast neoplasm) is a rare cancer in males that originates from the breast. Many males with breast cancer have inherited a BRCA mutation, but there are other causes, including alcohol abuse and exposure to certain hormones and ionizing radiation.

Request a sample Report of Male Breast Cancer Treatment Market at:https://www.marketstudyreport.com/request-a-sample/2181290?utm_source=coleofduty.com&utm_medium=Pravin

The latest report on the Male Breast Cancer Treatment market contains a detailed analysis of this marketplace and entails information about various industry segmentations. According to the report, the market is presumed to amass substantial revenue by the end of the forecast duration while expanding at decent growth rate.

Details regarding the industry size, remuneration potential, and volume share are compiled in the report. It further lists out the drivers and challenges that will impact the growth of Male Breast Cancer Treatment market during the estimated timeframe.

The Male Breast Cancer Treatment market with respect to the geographical terrain:

Ask for Discount on Male Breast Cancer Treatment Market Report at:https://www.marketstudyreport.com/check-for-discount/2181290?utm_source=coleofduty.com&utm_medium=Pravin

Additional highlights from the Male Breast Cancer Treatment market share report are enlisted below:

Table of Contents:

Executive Summary: It includes key trends of the Male Breast Cancer Treatment market share related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Male Breast Cancer Treatment market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Male Breast Cancer Treatment market.

Market Segments: This part of the report discusses about product type and application segments of the Male Breast Cancer Treatment market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-male-breast-cancer-treatment-market-2019-by-company-regions-type-and-application-forecast-to-2024

Some of the Major Highlights of TOC covers:

Male Breast Cancer Treatment Regional Market Analysis

Male Breast Cancer Treatment Segment Market Analysis (by Type)

Male Breast Cancer Treatment Segment Market Analysis (by Application)

Male Breast Cancer Treatment Major Manufacturers Analysis

Read More Related Reports at: https://www.marketwatch.com/press-release/2025-Tracheostomy-Market-Analysis-and-Size-report-will-reach-to-1993-Million-USD-at-CAGR-of-4-2020-06-19

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Original post:
Male Breast Cancer Treatment Market Size : Technological Advancement and Growth Analysis with Forecast to 2025 - Cole of Duty

These stories have nothing in common other than that they are fascinating examples of the way animals have evolved to suit their environments and lifestyles.

Researchers say they have discovered how Tibetan antelopes are able to run hard and fast despite living at altitude, and why Siamese fighting fish fight like they do.

In the first case, its a bit about staying young.

A study published in the journal Science Advances suggests that Pantholops hodgsonii has overcome oxygen deprivation on the high-altitude Tibetan Plateau through an unusual adaptation in which it permanently expresses a form of haemoglobin that other members of the cattle family only express as juveniles, or when under extreme oxygen deprivation.

Through a comparative genomic analysis with other bovids, Anthony Signore and Jay Storz from the University of Nebraska, US, found that the region that encodes for the adult form of haemoglobin was deleted in the antelopes ancestor, causing the juvenile form of the protein, which has a higher oxygen affinity, to take its place in adult red blood cells.

In other words, they say, a reversible response to oxygen deprivation previously documented in adult goats and sheep became a permanent genetic fixture in a mammal that is native to a region that ranges between 3600 and 5500 metres above sea level.

Through in vitro experiments, they confirmed that the antelopes haemoglobin does have a much higher oxygen affinity than that of all other bovids, perhaps explaining how it can run at 70 kilometres an hour over great distances, at altitudes where the partial pressure of oxygen is roughly half that at sea level.

In the second study, published in the journal PLOS Genetics, researchers from Japan, Taiwan, Saudi Arabia and the US reveal that when Siamese fighting fish are fighting, the gene expression in their brain cells starts to align.

Betta splendens is famous for its aggression, but male opponents modify their actions to match each others behaviour leading to tightly synchronised battles and typically stop fighting after assessing the others abilities to avoid any serious injuries, the researchers say.

When they analysed their brains, they observed that the opponents had similar changes in gene activity related to learning, memory, synapse function and ion transport across cell membranes.

This was specific to a fighting pair and became stronger after fighting for an hour, compared to 20 minutes, suggesting the degree of synchronisation is driven by fighting interactions.

Similar mirrored behaviours occur during mating, foraging and cooperative hunting, and these may also trigger synchronised brain changes in the pairs of animals.

One of my future plans is to elucidate what happens in the male-female interaction of fish on the molecular level, says lead author Norihiro Okada, from Kitasato University, Japan.

Read the original:
Aerobic antelopes and synchronised fish - Cosmos

19 June 2020

The findings, published in the Journal of Public Health, suggest that the relationship between COVID-19 infection and ethnicity is complex, and requires more dedicated research to explain the factors driving these patterns.

Growing international reports highlight higher risk of adverse COVID-19 infection in BAME populations. The underlying cause of this ethnicity disease pattern is not known. Variation in cardiovascular disease risk, vitamin D levels, socio-economic, and behavioural factors have been proposed as possible explanations. However, these hypotheses have not been formally studied in existing work.

Investigators from Queen Mary, in collaboration with the Medical Research Council Lifecourse Epidemiology Unit at the University of Southampton, used the comprehensive and unique UK Biobank cohort of over half a million people to investigate the role of a range of socioeconomic, biological, and behavioural factors in determining the ethnicity pattern of severe COVID-19. The dataset included 4,510 UK Biobank participants who were tested for COVID-19 in a hospital setting, of whom 1,326 had a positive test result.

The results demonstrate that BAME ethnicity, male sex, higher body mass index, greater material deprivation, and household overcrowding are independent risk factors for COVID-19. The higher rates of severe COVID-19 in BAME populations was not adequately explained by variations in cardiovascular disease risk, vitamin D levels, socio-economic, or behavioural factors, suggesting that other factors not included in the analysis might underlie these differences.

Dr Zahra Raisi-Estabragh, BHF Clinical Research Training Fellow at Queen Mary University of London, led the analysis. She said: There is increasing concern over the higher rate of poor COVID-19 outcomes in BAME populations. Understanding potential drivers of this relationship is urgently needed to inform public health and research efforts. This work goes some way in addressing some of these pertinent questions.

Steffen Petersen, Professor of Cardiovascular Medicine at Queen Mary University of London, who supervised the work added: The results of this analysis suggest that factors which underlie ethnic differences in COVID-19 may not be easily captured. In addition to assessment of the role of biological considerations such as genetics, approaches which more comprehensively assess the complex economic and sociobehavioural differences should now be a priority.

Nicholas Harvey, Professor of Rheumatology and Clinical Epidemiology at the MRC Lifecourse Epidemiology Unit, University of Southampton, was a key collaborator in the work. He comments: The detailed participant characterisation in the UK Biobank and the rapid linkage of this data with COVID-19 test results from Public Health England permitted consideration of potential importance of a wide range of exposures.

The work was also supported by the National Institute for Health Research (NIHR) through the Barts Biomedical Research Centre, NIHR Southampton Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre.

View post:
SMD - Higher rates of severe COVID-19 in BAME populations remain unexplained - QMUL

Genetically modified mosquitoes with the ability to prevent other mosquitoes from spreading deadly diseases may be making their way to Florida backyards in the near future.

British biotech group Oxitec announced on Tuesday that the company had won both federal and state approval to release its so-called Friendly mosquitoes in the U.S. on an experimental trial basis, expected to last until 2022, according to documents provided by the Environmental Protection Agency. The insects will first be released in Monroe County, Florida, and Oxitec has plans to also bring them to Harris County, Texas.

Oxitecs project involvesAedes aegypti, the mosquito that spreads yellow fever, dengue fever and Zika, among other diseases. While femaleAedes aegyptifeed on blood and are the transmitters of such illnesses, maleAedes aegypti are harmless, and Oxitecs Friendly mosquitoes are males who have been altered to carry a specificself-limiting gene, according to a description on the companys website. This gene will reduce the lifespan of any female offspring they might foster, but will live on in males, offering ... self-limiting generations of suppression that can lower the generalAedes aegypti population over time, theoretically leading to a decrease in the diseases that the insects are known for.

There is broad consensus amongst public health officials in the U.S. that a new generation of safe, targeted and cost-effective vector control tools are needed urgently to combat the growing threat posed by Aedes aegypti without impacting the ecosystem, Grey Frandsen, Oxitec CEO, said in the companys announcement. Were pleased that the EPA and Florida state regulators have, after extensive scientific reviews, approved our demonstration trials and we look forward to continuing the collaboration with our local partners as they take up the matter.

This novel method of mosquito population control was recently tested in the municipality of Indaiatuba, near So Paulo, Brazil, from May 2018 to 2019. In one of the tested communities, Oxitec observed that the genetically modified mosquitoes managed to suppress the population of Aedes aegyptiup to 96% within a four-week period.

Oxitecs work in mosquito genetics is not without controversy, and the company has targeted Florida as a testing ground for nearly a decade. AChange.org petition urging the EPA to reject the companys proposals, originally posted online in 2012, has received over 230,000 signatures, and the EPA is facingpre-litigation from advocacy groups, including the Center for Food Safety and Friends of the Earth U.S., for approving Oxitecs latest proposal.

Jaydee Hanson, policy director for the Center for Food Safety, called the mosquito project a Jurassic Park experiment in a statement. Hanson argued that by not carrying out in-depth consultations with local wildlife agencies before allowing Oxitec free rein with its insects, the EPA had unlawfully refused to seriously analyze environmental risks.

The Florida Keys and Houston and the surrounding communities are home to some of the most diverse and threatened species in our country, Dana Perls, food and technology program manager of Friends of the Earth U.S., echoed in the same statement. Once again, the Trump administration is callously disregarding scientific experts and the will of communities to force this risky experiment through.

Calling all HuffPost superfans!

Sign up for membership to become a founding member and help shape HuffPost's next chapter

Here is the original post:
Genetically Modified Mosquitoes Approved For Insect Population Control In The U.S. - HuffPost

The genetic make-up of an adult male buried in the heart of the ancient Newgrange passage tomb indicates he was among a ruling social elite and in-bred in a similar way to Inca god-kings and Egyptian pharaohs.

This remarkable discovery shedding new light on the earliest periods of Irelands human history has been made by archaeologists and geneticists led by a team in Trinity College Dublin. Their genetic analysis shows he was born as a consequence of first-degree incest.

Older than the pyramids, Newgrange passage tomb in Co Meath is world famous for its annual solar alignment where the winter solstice sunrise illuminates its sacred inner chamber in a golden blast of light. However, little is known about who was interred in the heart of this imposing 200,000-tonne monument or of the Neolithic society which built it more than 5,000 years ago.

The survey of ancient Irish genomes using DNA sequencing technology on bone samples suggests a man who had been buried in this chamber belonged to a dynastic elite, according to Dr Lara Cassidy of TCD, lead author of the research published by Nature scientific journal on Wednesday.

Id never seen anything like it, she said. We all inherit two copies of the genome, one from our mother and one from our father. This individuals copies were extremely similar, a tell-tale sign of close inbreeding. In fact, our analyses allowed us to confirm that his parents were first-degree relatives.

Matings of this type (such as brother-sister unions) are a near universal taboo for cultural and biological reasons. The only confirmed social acceptances of first-degree incest are found among the elites typically within a deified royal family, Dr Cassidy explained.

By breaking the rules, the elite separates itself from the general population, intensifying hierarchy and legitimising power. Public ritual and extravagant monumental architecture often co-occur with dynastic incest, to achieve the same ends, she added.

Here the auspicious location of the male skeletal remains is matched by the unprecedented nature of his ancient genome, said professor of population genetics at TCD Dan Bradley.

The prestige of the burial makes this very likely a socially sanctioned union and speaks of a hierarchy so extreme that the only partners worthy of the elite were family members.

The team also unearthed a web of distant familial relations between this man and others from sites of the passage tomb tradition across the country, namely the mega-cemeteries of Carrowmore and Carrowkeel in Co Sligo, and the Millin Bay monument in Co Down.

It seems what we have here is a powerful extended kin-group, who had access to elite burial sites in many regions of the island for at least half a millennium, Dr Cassidy said.

The monument builders were early farmers who migrated to Ireland and replaced hunter-gatherers who preceded them.

Remarkably, a local myth resonates with these results and the Newgrange solar phenomenon. First recorded in the 11th century AD, four millennia after construction, the story tells of a builder-king who restarted the daily solar cycle by sleeping with his sister. The Middle Irish place name for the neighbouring Dowth passage tomb Fertae Chuile is based on this lore and can be translated as Hill of Sin.

Given the world-famous solstice alignments of Br na Binne, the magical solar manipulations in this myth already had scholars questioning how long an oral tradition could survive, said Dr Ros Maoldin, an archaeologist on the study. To now discover a potential prehistoric precedent for the incestuous aspect is extraordinary.

The genome survey has unearthed other unexpected results. Within the oldest known burial structure on the island, Poulnabrone portal tomb, the earliest yet diagnosed case of Down Syndrome was discovered in a male infant who was buried there 5,500 years ago. Isotope analyses suggest the infant was breast-fed.

It was conducted in collaboration with researchers at University College London; NUIG, UCC, University of Cambridge, Queens University Belfast, Sligo IT and the National Monuments Service with support from the National Museum of Ireland and National Museums Northern Ireland.

See original here:
Newgrange tomb body belonged to royal-like male born of incest - The Irish Times

DetailsCategory: Proteins and PeptidesPublished on Thursday, 18 June 2020 09:51Hits: 112

June 17, 2020 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; JCR) announced today that the results of the phase 1 and 2/3 clinical trials of Agalsidase Beta BS I.V. Infusion [JCR] (JR-051), recombinant Agalsidase Beta, for Fabry disease have been published in the electronic edition of Molecular Genetics and Metabolism, the official journal of Society for Inherited Metabolic Disorders. This is JCRs first product for enzyme replacement therapy (ERT) for Lysosomal Storage Disorders (LSDs), also the first of the kind manufactured in Japan. Agalsidase Beta BS I.V. Infusion [JCR] has been launched since November 2018 as the first biosimilar for the treatment of rare diseases. A summary of the article is as follows.

Title: Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies

Digital Object Identifier: https://doi.org/10.1016/j.ymgme.2020.04.003

Summary The Phase 1 and 2/3 studies were conducted with the aim to verify clinical comparability of JR051 and an upfront biopharmaceutical (agalsidase beta). The results demonstrated that JR051 and agalsidase beta are comparable in terms of efficacy and safety.

Phase 1 study: 20 healthy adult male volunteers were administered JR-051 and agalsidase beta to confirm pharmacokinetic equivalence in a randomized, double-blind, parallel-group manner. The study demonstrated comparable pharmacokinetic profiles of JR-051 and agalsidase beta.

Phase 2/3 study: 16 patients with Fabry disease underwent treatment with agalsidase beta (1mg/kg, once every other week), then were switched to intravenous administrations of JR-051 (1 mg/kg, once every other week).

Efficacy: The 95% confidence intervals of the ratios of the GL-3 plasma concentrations (primary endpoint) during the agalsidase beta treatment, as well as those of Lyso-GL-3, to the respective plasma concentrations after 26 and 52 week-administrations of JR-051 were within pre-determined equivalence acceptability ranges.

Safety: No severe infusion associated reactions (IARs), such as anaphylactic shock, were observed. One IAR, commonly observed with the ERT for Fabry disease, was reported in a patient after JR-051 administration.

[About JCR Pharmaceuticals]

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, Contributing towards peoples healthcare through pharmaceutical products drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

SOURCE: JCR Pharmaceuticals

Read this article:
Agalsidase Beta BS IV Infusion [JCR] (JR-051) for Fabry Disease: Notice on the Publication of the Results of the Phase 1 and 2/3 Clinical Trials in...

Cancer can be a fatal disease, and the exact cause of cancer is still unknown. While many factors could lead to malignant disease, the reason is often based on estimation. The deadly disease affects both men and women alike, but a few types of cancer can be more dangerous in men than women. Genetics, lifestyle habits, and a few other factors make men more predisposed to certain types of cancer. Here are the most common types of cancer in men.

This is a no brainer as only men have the organ and so, women can't suffer from this cancer type. Every man should get a PSA test done after 50 years of age to check if their prostate is healthy. Prostate cancer can be a silent killer, and most often, an individual may not be aware unless one reaches the advanced stage.Mens Health Week 2020: From Cleaning Foot to Keeping Your Armpit Fresh, Here Are Five Personal Hygiene Habits Every Male Should Follow.

Tobacco use is more in men as compared to women which are a prime cause of lung cancer in men. That said, in recent times, there has been a rise in tobacco use in women. However, studies have shown that men are more at risk of lung cancer than women.Mens Health Week 2020: From Prostate Cancer To ED, Common Age-Related Health Problems In Men.

Bladder cancer is more common in men. A study published in the journal General Medicine where data was collected from both men and women who had bladder cancer showed that the male to female ratio was 2.2:1. The findings of the study also showed that the tumours were less aggressive and invasive in women as compared to men.

Did you know that men have a threefold higher risk of developing kidney cancer than women? Smoking, genetics and other occupational factors increase a man's chances of suffering from renal cell carcinoma. Plus, kidney cancer in men are characterised with larger tumours and are more aggressive.

While an equal number of men and women suffer from incidences of acute pancreatitis, chronic pancreatitis is more common in men. While men suffer from alcohol-related pancreatitis, in women, pancreatitis is more due to autoimmune diseases, gall stones and other factors.Men's Health Week 2020: Why Is Male Suicide Rate Higher? Know More About Mental Health Stigma.

Other forms of cancer like mouth and throat cancer and leukaemia are also more common in men than women. Men also tend to suffer from colorectal cancer, so clean eating and corrective lifestyle can save you big time!

(The above story first appeared on LatestLY on Jun 18, 2020 01:41 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).

View post:
Men's Health Week 2020: From Lung to Bladder, Types of Cancer that Can be More Dangerous in Men Than Women! - LatestLY

The impetus for the campaign can be traced back to a crime spree in the northern Chinese region of Inner Mongolia. For nearly three decades, the police there investigated the rapes and murders of 11 women and girls, one as young as 8. They collected 230,000 fingerprints and sifted through more than 100,000 DNA samples. They offered a $28,000 reward.

Then, in 2016, they arrested a man on unrelated bribery charges, according to the state news media. Analyzing his genes, they found he was related to a person who had left his DNA at the site of the 2005 killing of one of the women. That person, Gao Chengyong, confessed to the crimes and was later executed.

Mr. Gaos capture spurred the state media to call for the creation of a national database of male DNA. The police in Henan Province showed it was possible, after amassing samples from 5.3 million men, or roughly 10 percent of the provinces male population, between 2014 and 2016. In November 2017, the Ministry of Public Security, which controls the police, unveiled plans for a national database.

China already holds the worlds largest trove of genetic material, totaling 80 million profiles, according to state media. But earlier DNA gathering efforts were often more focused. Officials targeted criminal suspects or groups they considered potentially destabilizing, like migrant workers in certain neighborhoods. The police have also gathered DNA from ethnic minority groups like the Uighurs as a way to tighten the Communist Partys control over them.

The effort to compile a national male database broadens those efforts, said Emile Dirks, an author of the report from the Australian institute and a Ph.D. candidate in the department of political science at the University of Toronto. We are seeing the expansion of those models to the rest of China in an aggressive way that I dont think weve seen before, Mr. Dirks said.

In the report released by the Australian institute, it estimated that the authorities aimed to collect DNA samples from 35 million to 70 million men and boys, or roughly 5 percent to 10 percent of Chinas male population. They do not need to sample every male, because one persons DNA sample can unlock the genetic identity of male relatives.

Read the original here:
China Is Collecting DNA From Tens of Millions of Men and Boys, Using U.S. Gear - The New York Times

Mens Health Week 2020: Prostate cancer and other common health problems in Indian men; how to prevent them  |  Photo Credit: iStock Images

New Delhi: Its Men s Health Week, which is observed every year leading up to Fathers Day. The main objective of the week is to raise awareness of health problems that are preventable as well as encourage early detection and treatment of diseases that affect men and boys. Experts say only 30 per cent of a mans overall health is determined by his genetics, and 70 per cent is controllable through his lifestyle. Studies show that men live almost 9 years in poor health in their lifetime - which can be prevented by making small lifestyle changes.

The observance is a reminder for men to take steps for a healthier, longer life - yet, they do not have to do it alone. All of us can help support the health and safety of the men in our lives - whether its your husband, son, dad, brother, or friend. The 2020 Mens Health Week is being observed amid the novel coronavirus pandemic, hence, the theme, Take Action on Covid-19. This year, the week runs from 15-21 June. On the occasion of Mens Health Week, Dr Govardhan Reddy, Lead Consultant - Urology and Uro Oncology, Aster CMI Hospital, Bangalore, talked about the common health problems that affect Indian men and what they can do to prevent them.

Some of the common health issues plaguing Indian men include - prostate cancer, erectile dysfunction, infertility and impotency, heart disease, etc. Apart from this, comorbidities like diabetes, hypertension, obesity, cancer and mental health disorders with daily alcohol intake are some of the largest gender health gaps.

Available evidence indicates that young people are prone to a number of conditions due to personal choices, environmental influences and lifestyle changes. Nutritional disorders (both malnutrition and over-nutrition), tobacco use, harmful alcohol use, other substance use, high-risk sexual behaviors, stress, common mental disorders, and injuries (road traffic injuries, suicides, and violence of different types) specifically affect this population and it has a long-lasting impact.

Talking about prostate cancer, it is advisable for men with a family history ofthe condition to undergo a mandatory screening with the consultant urologist after the age of 45 regardless of any symptoms which comprise of frequent and difficult urination, weak urine stream, blood in semen, pelvic pain or stiffness and erectile dysfunction.

Renal transplant surgeons stress on the use of tobacco as the main cause for cancers in kidney and bladder. Smoking or vaping is also harmful to erectile functions and increases male infertility.

Also, people working in the tar and painting industries or factories carry high risk for bladder cancers. Similarly, fatty diets are known to cause a higher risk for prostate cancer and stone diseases, in order to prevent them it is better to have 2-3 litres of water per day.

Fortunately, many of mens health issues can be prevented or treated if diagnosed early. Here are a few things men can do to prevent or reduce their risk of common health problems:

Making healthier lifestyle choices will not only help prevent or reduce disease risk, but it will also give you an opportunity to enjoy the years of life available to each person.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Read more here:
Mens Health Week 2020: Prostate cancer and other common health problems in Indian men; how to prevent them - Times Now

Ginalski K, Rychlewski L, Baker D, Grishin NV. Protein structure prediction for the male-specific region of the human Y chromosome. Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2305-10.

Jain M, Olsen HE, Turner DJ, Stoddart D, Bulazel KV, Paten B, Haussler D, Willard HF, Akeson M, Miga KH. Linear assembly of a human centromere on the Y chromosome. Nat Biotechnol. 2018 Mar 19. doi: 10.1038/nbt.4109. [Epub ahead of print]

Krausz C, Casamonti E. Spermatogenic failure and the Y chromosome. Hum Genet. 2017 May;136(5):637-655. doi: 10.1007/s00439-017-1793-8. Epub 2017 Apr 29. Review.

Krausz C, Quintana-Murci L, Forti G. Y chromosome polymorphisms in medicine. Ann Med. 2004;36(8):573-83. Review.

Liu XG, Hu HY, Guo YH, Sun YP. Correlation between Y chromosome microdeletion and male infertility. Genet Mol Res. 2016 Jun 3;15(2). doi: 10.4238/gmr.15028426.

Noordam MJ, Repping S. The human Y chromosome: a masculine chromosome. Curr Opin Genet Dev. 2006 Jun;16(3):225-32. Epub 2006 May 2. Review.

Rizvi AA. 46, XX man with SRY gene translocation: cytogenetic characteristics, clinical features and management. Am J Med Sci. 2008 Apr;335(4):307-9. doi: 10.1097/MAJ.0b013e31811ec1b4.

Russo P, Siani A, Miller MA, Karanam S, Esposito T, Gianfrancesco F, Barba G, Lauria F, Strazzullo P, Cappuccio FP. Genetic variants of Y chromosome are associated with a protective lipid profile in black men. Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1569-74. doi: 10.1161/ATVBAHA.108.168641. Epub 2008 May 29.

Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, Cordum HS, Hillier L, Brown LG, Repping S, Pyntikova T, Ali J, Bieri T, Chinwalla A, Delehaunty A, Delehaunty K, Du H, Fewell G, Fulton L, Fulton R, Graves T, Hou SF, Latrielle P, Leonard S, Mardis E, Maupin R, McPherson J, Miner T, Nash W, Nguyen C, Ozersky P, Pepin K, Rock S, Rohlfing T, Scott K, Schultz B, Strong C, Tin-Wollam A, Yang SP, Waterston RH, Wilson RK, Rozen S, Page DC. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature. 2003 Jun 19;423(6942):825-37.

Tartaglia N, Davis S, Hench A, Nimishakavi S, Beauregard R, Reynolds A, Fenton L, Albrecht L, Ross J, Visootsak J, Hansen R, Hagerman R. A new look at XXYY syndrome: medical and psychological features. Am J Med Genet A. 2008 Jun 15;146A(12):1509-22. doi: 10.1002/ajmg.a.32366.

Visootsak J, Graham JM Jr. Klinefelter syndrome and other sex chromosomal aneuploidies. Orphanet J Rare Dis. 2006 Oct 24;1:42. Review.

Visootsak J, Rosner B, Dykens E, Tartaglia N, Graham JM Jr. Behavioral phenotype of sex chromosome aneuploidies: 48,XXYY, 48,XXXY, and 49,XXXXY. Am J Med Genet A. 2007 Jun 1;143A(11):1198-203.

Walzer S, Bashir AS, Silbert AR. Cognitive and behavioral factors in the learning disabilities of 47,XXY and 47,XYY boys. Birth Defects Orig Artic Ser. 1990;26(4):45-58.

Waters PD, Wallis MC, Marshall Graves JA. Mammalian sex--Origin and evolution of the Y chromosome and SRY. Semin Cell Dev Biol. 2007 Jun;18(3):389-400. Epub 2007 Feb 24. Review.

Willard HF. Tales of the Y chromosome. Nature. 2003 Jun 19;423(6942):810-1, 813.

Originally posted here:
Y chromosome - Genetics Home Reference - NIH

The study on Global Male Breast Cancer Market, offers deep insights about the Male Breast Cancer Market covering all the crucial aspects of theMarket. Some of the important aspects analyzed in the reportincludesMarket share, production, key regions, revenue rate as well as key players. This Male Breast Cancer report also provides the readers with detailed figures at which the Male Breast Cancer Market was valued in the historical year and its expected growth in upcoming years. Besides, analysis also forecasts the CAGR at which the Male Breast Cancer is expected to mount and major factors driving Markets growth. This Male Breast Cancer Market was accounted for USD xxx million in the historical year and isestimated to reach at USD xxx million by the end of the forecast period, rising at a CAGR of xx%.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4697601?utm_source=Ancy

Market research reports play anextremely important role in refining the productivity of anindustry. The information in this reports will help the companies to make informed Marketing strategies. Moreover,ultimate goal of Market research is to analyze how the Markets target group will obtain a product or service. Market research report is predominantly prepared following certain methodology and guidelines for collecting, organizing and analyzing data. The research report on Global Male Breast Cancer Market has been very well drafted for the benefit of the readers who are looking forward to invest in the Market. Besides, focusing on overall aspects of the Market this report majorly covered profiles of the top big companies along with their sales data, etc.It also delivers the business models, strategies, growth, innovations and every information about key manufacturers that will enable in making business estimates.

Major companies of this report:

PfizerRocheGlaxoSmithKlineSanofiNovartisBayerBristol-Myers SquibbEli LillyAstraZenecaTeva PharmaceuticalSun PharmaceuticalBioNumerik PharmaceuticalsSeattle GeneticsAccord Healthcare

Browse the complete report @ https://www.orbisresearch.com/reports/index/male-breast-cancer-market-research-global-status-and-forecast-by-geography-type-and-application-2016-2026?utm_source=Ancy

In addition, every Market has a set of manufacturers, vendors and consumers that define the Market as well as their every moves and achievements becomes a subject of studying for Market analysts. Moreover, reports offers Market competition through region segmentation of Markets that enables in thorough analysis of the Market in terms of revenue generation potential, demand & supply comparison, business opportunities and future estimates of the Market. The annual progression for the Global Male Breast Cancer Market in different regions cannot always be listed down as it will keep changing, thus studying and reviewing Markets occasionally becomes vital. Major regions highlighted for the Global Male Breast Cancer Market report, include North America, South America, Asia, Europe and Middle East.

Segmentation by Type:

MedicationChemotherapyOthers

Segmentation by Application:

HospitalsClinicsOthers

Market research report on the Global Male Breast Cancer Market, also has the Market analyzed on the basis of different end user applications and type. End user application segments analysis allowsdefining the consumer behavior as well. It ishelpful to investigate product application in order toforetell the products outcome. Analyzing different segment type is also crucial aspect. It helps determine which type of the product orservice needs improvement. When reports are product centric, they also includes information about sales channel, distributors, traders as well as dealers. This facilitates effective planning as well as execution of the supply chain management. In a nutshell, a Market research report is through guide of a Market that aids the better Marketing and management of businesses.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4697601?utm_source=Ancy

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Read the original here:
Global Male Breast Cancer Market 2020 by Type of Service Offered, Manufacture, Statistics, Share, Growth, Revenue, Regions, and Business Opportunities...

SOUTH BEND, Ind. Clark Lea started texting and calling, wanting to talk but needing to listen. When he got to Daelin Hayes, the conversation compelled Lea to do more.

Notre Dames defensive coordinator had already seen the video of George Floyd under the knee of Minneapolis police officer Derek Chauvin. He had followed from a distance as anger at Floyds death boiled over in protests across the country. Lea didnt have a solution for any of it, other than to reach out to his players.

The words of Notre Dames fifth-year defensive end stopped Lea cold. They talked about Hayes life experience and the reality that faces Notre Dames defensive roster, where black players make up a majority. Hayes took those experiences and translated them for Lea, who has three kids.

Imagine sending your son out into the world and it sees him as a threat, Hayes told Lea. And you dont know if hes gonna...

More:
How Notre Dame empowered its players to speak out, and why it needs to listen - The Athletic

A new study, lead by University of Wyoming Ph.D. candidate Melanie LaCava, has been studying the genetics of Wyomings pronghorn herds. Wyoming is home to roughly half of North Americas pronghorn population approximately 750,000 individuals. Their findings show that, despite multiple mountain ranges, three major highways, and ranges that span hundreds of miles, Wyomings pronghorn have little-to-no genetic differentiation. Despite the massive barriers across the state, in doesnt seem to have caused any changes amongst pronghorn.

On a genetic level, they all look pretty much alike.

The study included sample collection from 2014 thru 2019, examined genetic data of 398 male and female pronghorn across Wyoming, excluding Yellowstone and Grand Teton national parks. While certain surprising, this lack of diversity makes sense given how the animals behave. Pronghorn are social animals, but many do not live in the same groups for their whole lives. They enjoy a much more flexible social structure than Wyomings other hoof stock. Many dont even consistently migrate. To LaCava, it shows the connectivity of all of the states pronghorn. All the barriers, human or natural, have not stopped them from mingling with their peers. But this does not detract from the importance of preserving their migration corridors and core habitats we want to ensure their populations stay happy and healthy.

You can examine the full study Pronghorn Population Genomics Show Connectivity in the Core of Their Range in the online publication Journal of Mammalogy.

Follow this link:
Little to No Genetic Differentiation in Wyoming's Pronghorn | - mybighornbasin

The study on Global Male Breast Cancer Treatment Market, offers deep insights about the Male Breast Cancer Treatment Market covering all the crucial aspects of theMarket. Some of the important aspects analyzed in the reportincludesMarket share, production, key regions, revenue rate as well as key players. This Male Breast Cancer Treatment report also provides the readers with detailed figures at which the Male Breast Cancer Treatment Market was valued in the historical year and its expected growth in upcoming years. Besides, analysis also forecasts the CAGR at which the Male Breast Cancer Treatment is expected to mount and major factors driving Markets growth. This Male Breast Cancer Treatment Market was accounted for USD xxx million in the historical year and isestimated to reach at USD xxx million by the end of the forecast period, rising at a CAGR of xx%.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4697602?utm_source=Ancy

Market research reports play anextremely important role in refining the productivity of anindustry. The information in this reports will help the companies to make informed Marketing strategies. Moreover,ultimate goal of Market research is to analyze how the Markets target group will obtain a product or service. Market research report is predominantly prepared following certain methodology and guidelines for collecting, organizing and analyzing data. The research report on Global Male Breast Cancer Treatment Market has been very well drafted for the benefit of the readers who are looking forward to invest in the Market. Besides, focusing on overall aspects of the Market this report majorly covered profiles of the top big companies along with their sales data, etc.It also delivers the business models, strategies, growth, innovations and every information about key manufacturers that will enable in making business estimates.

Major companies of this report:

PfizerRocheGlaxoSmithKlineSanofiNovartisBayerBristol-Myers SquibbEli LillyAstraZenecaTeva PharmaceuticalSun PharmaceuticalBioNumerik PharmaceuticalsSeattle GeneticsAccord Healthcare

Browse the complete report @ https://www.orbisresearch.com/reports/index/male-breast-cancer-treatment-market-research-global-status-and-forecast-by-geography-type-and-application-2016-2026?utm_source=Ancy

In addition, every Market has a set of manufacturers, vendors and consumers that define the Market as well as their every moves and achievements becomes a subject of studying for Market analysts. Moreover, reports offers Market competition through region segmentation of Markets that enables in thorough analysis of the Market in terms of revenue generation potential, demand & supply comparison, business opportunities and future estimates of the Market. The annual progression for the Global Male Breast Cancer Treatment Market in different regions cannot always be listed down as it will keep changing, thus studying and reviewing Markets occasionally becomes vital. Major regions highlighted for the Global Male Breast Cancer Treatment Market report, include North America, South America, Asia, Europe and Middle East.

Segmentation by Type:

MedicationChemotherapyOthers

Segmentation by Application:

HospitalsClinicsOthers

Market research report on the Global Male Breast Cancer Treatment Market, also has the Market analyzed on the basis of different end user applications and type. End user application segments analysis allowsdefining the consumer behavior as well. It ishelpful to investigate product application in order toforetell the products outcome. Analyzing different segment type is also crucial aspect. It helps determine which type of the product orservice needs improvement. When reports are product centric, they also includes information about sales channel, distributors, traders as well as dealers. This facilitates effective planning as well as execution of the supply chain management. In a nutshell, a Market research report is through guide of a Market that aids the better Marketing and management of businesses.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4697602?utm_source=Ancy

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Continue reading here:
Global Male Breast Cancer Treatment Market 2020 Technology Development, Industry Trends, Business Prospects, Top Key-Players, New Innovations and...

An irresponsible international food industry must shoulder a hefty part of the blame for COVID-19s deadly toll, say the authors of an editorial published yesterday in the BMJ. Moreover, to combat the parallel pandemic of obesity, governments need to step in to force reformulation of processed foods and prohibit the promotion of unhealthy eating that is causing so much morbidity and mortality worldwide, they say.

It's like tobacco, said Graham A. MacGregor, MB BChir, who co-authored the editorial with Monique Tan, PhD, and Feng J. He, PhD (all Queen Mary University of London, England). Why should the food industry be able to advertise things that are going to kill you?

Tan and colleagues review the evidence to date showing obesity to be an independent risk factor for more-severe illness and death following SARS-CoV-2 infection. These include a 428,225-patient cohort study showing that of 340 people requiring hospitalization, 44% were overweight and 34% were obese. Theres also the OpenSAFELY study, which looked at more than 12 million electronic records: among the 5,683 patients who died, 29% were overweight and 33% were obese. Both studies, note Tan et al, showed a dose-response relationship between excess weight and disease severity. In OpenSAFELY, the risk of dying from COVID-19 increased by 27% among obese individuals and was doubled in patients with a body mass index greater than 40.

I think people have recognized now that based on every study you look atincluding the early studies in China which were open studies, then from Europe, then from New Yorkthey all show that obesity increases the severity of COVID-19 and increases mortality, MacGregor observed.

Why should the food industry be able to advertise things that are going to kill you? Graham MacGregor

The only other major risk factors, he continued, are male sex and older age. If you're elderly and male and obese, I would be seriously worried and would do anything to try and lose weight and eat more healthily and take more exercise, MacGregor urged. Those are sensible things to do and the government should be encouraging people to do that, but of course they're not.

Speaking with TCTMD, MacGregor stressed that the blame rests with government and industry. One of the very clear messages that we want to give out, which is absolutely true, is that it's not the fault of the individuals that they are overweight; it's the fault of the food industry, because they promote all this very cheap processed foods that are made delicious by adding huge amounts of salt, sugar, and fat, and they then spend billions of pounds advertising this rubbish at very cheap prices, particularly targeted at socially deprived people and, not surprisingly, they're obese.

This allegation has particular resonance as protestors around the globe continue to call for an end to racism affecting the day-to-day lives of black, indigenous, and people of color who have also seen some of the highest levels of fatalities from COVID-19. In editorials and blogs, healthcare leaders have called on their colleagues to educate themselves about the problem and do their part to eradicate healthcare disparities.

There are a number of theories as to why obesity is amplifying disease severity. One is the chronic inflammatory state seen in obesity, which could play a role in the bodys altered immune response to SARS-CoV-2, potentially weakening the host defense and increasing the likelihood of the dreaded cytokine storm. A second possibility relates to the fact that angiotensin-converting enzyme 2 (ACE2), which SARS-CoV-2 uses to penetrate the cell membrane, is more common in people with obesity. Whether this is the result of higher ACE2 expression in the adipocytes of people with obesity or having more adipose tissue in general (and thus a greater number of ACE2-expressing cells) is not yet clear, the authors state.

A third possibility is the diminished lung function and difficulties with diaphragm contractility in people with massive abdominal obesity, creating more airway resistance and a lowered ability to fully expand the lungs. When patients with obesity need to be admitted to intensive care units, it is challenging to improve their oxygen saturation levels and ventilate them, Tan et al note.

Yet another option, potentially related to the immune system response, is genetics, MacGregor said, adding that this is an area of active investigation for which answers may come in a matter of months. But he dismissed the idea that an underlying genetic predisposition to obesity might also increase vulnerability to the virus. Obesity is only very rarely genetic, he insisted. Its an environmental disease, largely brought on by the food industry. The recent and ballooning numbers of obese people in China, India, and Vietnam as the fast-food and processed-food industries have started to flourish in these regions bear this theory out, he added.

Both MacGregor and He are involved with a range of blood pressure advocacy groups that have targeted high-sodium foods and added salt. Speaking with TCTMD, MacGregor used the successful salt reformulation campaigns in the United Kingdom as an example of what similar strategies targeting high-fat/high-calorie processed foods could accomplish with government support.

Of note, despite MacGregors longstanding interest in blood pressure, hes not convinced that hypertension on its own is an important risk factor for COVID-19, pointing to UK studies in which hypertension as a predictor for disease severity and death disappears after adjusting for age, race, sex, and obesity. Again, its early days and we are very cautious in drawing any conclusions from these [observational] studies because we're going to need much bigger studies, but my view is if blood pressure is a risk, it's a fairly small one compared to obesity, he commented.

Stop the Tide

MacGregor and colleagues conclude by calling on the food industry to immediately stop promoting high-fat, high-salt, high-sugar foods, and for governments to mandate the reformulation of unhealthy food and drink. Reducing salt, sugar, and saturated fat across the board would improve the diet of the entire population and bring even greater benefits for people who are most socially deprived, they write. The toll of morbidity and mortality from COVID-19 has made this more apparent and more urgent than ever.

Ironically, MacGregor said, at least in the UK, all the work that was going on to try and do something about obesity with the food industry has been abandoned because of the acute urgency of treating people with COVID-19.

The result has been a collision of two pandemics, he argued, the acute pandemic of COVID-19 and the chronic pandemic of obesity. And the two interact, MacGregor continued. Our feeling is that this is a time when governments need to act to do something not only about COVID-19 to try to stop the next wave of the infection or the current infection, but also to do something about obesity.

People with underlying obesity and obesity-related chronic diseases are at much higher risk for poor outcome: the virus may not be preventable, but those conditions are. Marion Nestle

Cardiologists have a role to play, he added. They should already be aware of the fact that unhealthy diet . . . is the biggest cause of death and disability in the world, he said. But we need to get many more physicians involved in trying to get their own governments and the food industry to do something about about preventing obesity rather than causing it, and COVID-19 has just brought that home again.

That message needs to be heard on the other side of the Atlantic as well, agreed Marion Nestle, PhD (New York University, NY), who commented on the editorial for TCTMD. The coronavirus pandemic has revealed a great deal about inequities and contradictions in food systems in the US as well as in the UK, she said in an email.People with underlying obesity and obesity-related chronic diseases are at much higher risk for poor outcome: the virus may not be preventable, but those conditions are.

What the pandemic has made clear, she added, is that preventing obesity is a societal responsibility, more than a personal one. It reveals the need to create food systems and food environments that support healthy eating and that make healthier foods more available, accessible, and affordable.

Regulation of the food industry, she added would help a lot with this.

Read more:
Obesity's Role in COVID-19 Deaths: Big Food, Slow Government to Blame? - TCTMD

For Yan Dekel and his husband, Alex Maghen - who host Daddy Squared: The Gay Dads Podcast - welcoming twin boys via surrogacy four years ago has been the biggest blessing of their lives.

"Our kids were born when I was 47 years old, and we decided to look into surrogacy when I was around 45 or 44," Alex told POPSUGAR. "I had always wanted to have children, but obviously one of the big differences between being a gay couple and a straight couple is that many straight couples can have a bottle of wine at dinner and nine months later a child is born. For a gay couple, it's often a much more careful and thoughtful process."

Related: After Years of Disappointment, Surrogacy Finally Gave Me the Chance to Be a Parent

Alex and Yan's reasoning for going the surrogacy route was straightforward: they wanted to have a genetic connection to their children. "Both Alex and I were very curious to see what our own genes would look like," Yan explained. "Part of my perception about having kids had a lot to do with the commitment I wanted to make to Alex. To me, my reason for wanting kids is very romantic. I wanted my genetics to be connected with Alex's forever so that if, God forbid, something happens between us, we'll always be together in a way."

"When the first child came out, we both burst out laughing because it was so obvious which kid had our DNA."

The pair enlisted the help of a surrogacy agency, which gave them access to a bank of women who were willing to donate their eggs. "We went through dozens of profiles and we came up with five finalists," Yan said. "Then we asked our closest friends and family to help us choose between the five. We ended up having three viable embryos: two male ones, which were given the quality grade of AA, and a girl one, which was graded BB. We froze them, and then waited to be matched with a surrogate. We were matched about four months after."

Although Yan and Alex didn't necessarily care about the sex of their children, they knew they wanted twins due to their age. Because of Yan and Alex's age, they wanted to try for two babies at once, and because they didn't care about their children's sex, they chose to implant the best-quality embryos. Having twins is considered to be a high-risk pregnancy, so representatives suggested trying for just one child at first. Set on having twins, they stuck to their original plan.

Story continues

"During stressful experiences, it's easy to turn over and allow the experts to tell you what to do," Alex said. "And I think it's important to feel confident that what your heart desires is what you want to get, and go for it."

"There are ways to save money, but it's definitely going to cost a lot of money."

Their surrogate gave birth to biological half-brothers: one boy's DNA comes from Yan, while the other's comes from Alex. And although the couple didn't want to know which son took after which dad, they figured it out the second the babies were born with one look at their hair. "Right before we went into the delivery room, the doctor told us that she was capable of doing an instant genetic test to tell which one was which," Alex explained. "We immediately said no and that we didn't care, except when the first child came out, we both burst out laughing because it was so obvious which kid had our DNA."

For these dads, few things were more surprising than how much biology played a part in everything from their children's mannerisms to the types of music they like. "It's really an amazing sociological experiment," Alex said. "Our boys are 4 years old and they've been raised the same way, they've had the same home environment, attend the same school, and they eat the same food, yet one of them conducts himself so much like me, and one of them conducts himself so much like Yan."

Yan agreed: "Alex and I sometime joke that we cloned ourselves. It's amazing to see how much genes hold. It's not only that they physically resemble us, but their personalities do, too - including their tastes in food! What's been amazing to me is that Alex's biological son sometimes speaks in a heavy Philadelphian accent when he's upset. Neither Alex nor I have this accent, but Alex's mother does since his family is originally from Philadelphia!"

Related: Surrogacy Was a More Emotional Journey Than I Ever Expected -but So Worth It

For parents considering surrogacy, the couple recommends that people weigh all their options before fully committing.

"There's a lot of research that you can and should do," Alex said. "It's also going to cost a lot of money. There are ways to save money, but it's definitely going to cost a lot of money, and that's something you have to be prepared for. In a cold, hard way of putting it, surrogacy is a lot like buying a house. It's a big expense. It's a big undertaking. It can be stressful. And I think that you need to go into it feeling confident that you know what you want and not allowing other people to tell you how to do it."

Read the rest here:
2 Dads Share What It Was Like to Have Genetically Tied Twins Using a Surrogate - It's Incredible - Yahoo Lifestyle

Detraining is a natural physiological phenomenon that plays out in the body when an athlete ceases regular training. Any swimmer who has ever followed an intense season with a 2-3-week break and then returned to face the music will know what whats gained in three weeks is lost in a day feels like.

Forced lockdown during COVID-19 has broughtdetraining into sharp focus as swimmers, coaches and programs make their way back to water and pool deck.

To use the words of Pieter van den Hoogenbands dad Dr Cees-Reinvan den Hoogenband:

detraining results in a diminished efficiency of heart and lungs to transport oxygen and use this in active muscles (i.e. reduced cardio-respiratory efficiency, and a diminished capacity of skeletal muscle to display strength, flexibility and endurance (i.e. reduced musculoskeletal capability). Given the changes in energy expenditure, individual nutritional requirements will also change.

Dr. Van den Hoogenband, in his role as the chairman of the FINA Sports Medicine Committee advising the FINA COVID-19 Task Force backed by guidance from the World Health Organisation(WHO) and Government Agencies, issued a statement this week to coincide with the permissions being granted or considered by Public Health Authorities in many countries for a limited return to swimming pools and on the understanding that hygiene measures, hand washing, physical distancing and contact tracing initiatives are observed.

As we noted in a two-art feature with water health and hygiene expert Dr. Vincenze Spica (part 1 ; Part 2), there are reasons to be optimistic, reasons why elite swimming in control conditions can be revived. There are also, say scores of experts, cautionary measures that need to be observed at a time when more needs to be known about the nature of the novel coronavirus behind the current pandemic in which 7.6m people have been infected and more than 424,000 have died as a result of COVID-19, according to official registered statistics.

In his nite to swimmers, coaches and programs, Dr. Van den Hoogenband raises an issue critical to the health, welfare and successful return of athletes. He writes:

The SMC respectfully reminds all stakeholders that athletes, forced into an unprecedented and prolonged break from habituated training routines, may experience the physical effects of detraining.

For professional athletes with access to expertise in sports science and medicine, we understand that these issues will have already been anticipated and, to some extent, minimised by land-based exercise. However, many FINA athletes do not enjoy these privileges and it is inevitable that all athletes will be affected to some extent. Sport specific fitness for aquatic athletes can only be fully achieved through water-based activities.

The SMC wishes to raise these issues for the benefit of all aquatic athletes. We advise a gradual resumption of training, balancing water-based and land-based activities and increasing these elements slowly, starting with low and medium intensity exercise. This will allow your body to readjust and minimise the risk of overuse injury through failure to adapt to increasing workload. Rising energy demands of training will also require appropriate nutritional intake.

We also appreciate the psychological impact the COVID-19 pandemic has had on athletes, affecting normal interactions and routines, and as a consequence of postponement or cancellation of FINA events. Return to competition fitness will take several months and FINA will take this into account when making future decisions.

As Dr Van den Hoogenband noted, many of the worlds best swimmers and their coaches have access to experts and good resources when it comes to detraining. Iigo Mujika, the physiologist who works with coach Fred Vergnoux and team at Spanish swimming, is among those who has long considered the theme in academic work that feeds into the coaching of world-class swimmers, among other athletes.

Detraining is nothing new. Back in the days of the GDR, swimmers were detrained for up to two years after their last races, Kornelia Ender revealing back in 1993 in an interview with this author that she swam down and eased out of the sport over a period of almost two years. Part of the reason for that, according to medical papers recovered from Stasi (state police) files after the fall of the Berlin Wall in 1989, was to attempt to reverse the androgenization of girls fed steroids since they were 13 years old. The issues raised are relevant to the current debate on gender in sport. Like so many things in this world, there is a light and dark side to the coin of knowledge.

Understanding detraining and taking the theme into account as swimming programs embrace a steady revival speaks to the best interests of athletes (including those who were abused with doping from a young age). Science developed in the GDR in what was the biggest experiment ever undertaken on athletes (an estimated 10,000 were affected), made its way to the library of understanding in world swimming long ago. Science does not stand still, of course, and much more has been learned since Ender and Co were swum down.

In 2001, Mujika co-authored a paper with Sabino Padillain which they considered the Cardiorespiratory and metabolic characteristics of detraining in humans (available free at that link). They wrote:

Detraining can be defined as the partial or complete loss of training-induced adaptations, in response to an insufficient training stimulus. Detraining is characterized, among other changes, by marked alterations in the cardiorespiratory system and the metabolic patterns during exercise. In highly trained athletes, insufficient training induces a rapid decline in O2max, but it remains above control values. Exercise heart rate increases insufficiently to counterbalance the decreased stroke volume resulting from a rapid blood volume loss, and maximal cardiac output is thus reduced. Cardiac dimensions are also reduced, as well as ventilatory efficiency. Consequently, endurance performance is also markedly impaired.

These changes are more moderate in recently trained subjects in the short-term, but recently acquired O2max gains are completely lost after training stoppage periods longer than 4 wk. From a metabolic viewpoint, even short-term inactivity implies an increased reliance on carbohydrate metabolism during exercise, as shown by a higher exercise respiratory exchange ratio. This may result from a reduced insulin sensitivity and GLUT-4 transporter protein content, coupled with a lowered muscle lipoprotein lipase activity. These metabolic changes may take place within 10 d of training cessation. Resting muscle glycogen concentration returns to baseline within a few weeks without training, and trained athletes lactate threshold is also lowered, but still remains above untrained values.

Their conclusion reads: Detraining, defined as the partial or complete loss of training-induced adaptations in response to an insufficient training stimulus, may take place within short periods of training cessation or marked reduction in habitual physical activity level. Short-term cardiorespiratory detraining is characterized in highly trained athletes by a rapid O2max decline, but it usually remains above sedentary values. O2max decreases to a lesser extent in recently trained subjects in the short run, but training-induced gains are most often completely reversed when training is stopped for a period longer than 4 wk. The O2max loss is the outcome of an immediate reduction in total blood and plasma volumes, the latter being caused by a reduced plasma protein content.

Even though exercise heart rate increases at both maximal and submaximal intensities, this is not sufficient to counterbalance the reduced stroke volume, and maximal cardiac output declines. Cardiac dimensions often decrease, blood pressure increases, and ventilatory efficiency is most usually impaired after periods of training cessation. This general loss in cardiorespiratory fitness results in a rapid decline in the trained athletes endurance performance. Recently acquired endurance performance gains, on the other hand, can be readily maintained for at least 2 wk without training.

From a metabolic perspective, even short-term detraining is characterized by a higher reliance on carbohydrate as a fuel for exercising muscles, as indicated by an increased respiratory exchange ratio. Whole-body glucose uptake is reduced, because of a decline in insulin sensitivity and a reduced muscle GLUT-4 transporter protein content, both in athletes and in recently trained individuals. In addition, muscle lipoprotein lipase activity decreases. Exercise blood lactate concentration increases at submaximal intensities, and the lactate threshold is apparent at a lower percentage of O2max. These changes, coupled with a base deficit, result in a higher postexercise acidosis. Finally, muscle glycogen concentration suffers a rapid decline, reverting to sedentary values within a few wk of training cessation.

Dr. G. John Mullen recently published the highlights of a conversation he had with Dr. Rodrigo Zacca, Ph.D, a Postdoctoral Researcher of Universidade do Porto in Portugal. Dr. Zacca studied the Effects of detraining in age-group swimmers performance, energetics and kinematics.

On his Swimming Science blog, Dr. Mullenpenned the 9 Things you Didnt Know about Swimming Detraining as a result of his conversation with Dr. Zacca. Here are the seven themes covered (read the article in full at Swimming Science for the detail):

Swimming Impairs: the main conclusions of this study suggest that detraining after four-weeks of pool-based training cessation can impair swimming performance at the start of the following training season in age-group swimmers, underlining the importance of maintaining fitness levels during off-season or swimming detraining.

3.8% Impairment: The 400-m front crawl performance of 1415 years old competitive swimmers was impaired by ~3.8% after four-weeks of training cessation

No Effects from Growth: Four-weeks was not long enough to detect growth effect on performance, but impairment of 400m front crawl performance was attenuated by those swimmers who were more physically active during the off-season.

Elite Swimmers 4-Week Detraining: For elite swimmers, there are three interesting studies.

High-Intensity Maintains Performance: Non-swimming specific physical activities during the offseason or swimming detraining accounted for 40% of the total variance in performance, showing good partial correlation with impairment in performance

How Long to Get In Swimming Shape After Covid-19: Many factors will influence the length of time for recovery from Covid-19. Size and speed to reverse these losses after the #Covid19 will depend on many aspects, such as current fitness level, training history, age, specificity of previous training, and even genetics (Mujika and Padilla 2000-01; Abrahin et al. 2019). However, since the pandemic is not over yet and we do not know when it will end, its time to attenuate the impairments in performance. Those who manage to remain more active (in a creative and intelligent way) will have fewer problems after this pandemic period.

Other Tips on Limiting Impairments from Swimming Detraining: First, dont stand waiting for the end of pandemic, as the impairments can be irreversible Second, be creative to create alternatives, but be intelligent (specificity matters a lot).

Dr Mullen notes that study of detraining and related issues was not the exclusive preserve of sport and the theme dovetails with other important factors in performance swimming, such as injury, health, disease; Taper; Off-season; and now a pandemic.

Understanding the effects of training reduction and cessation is of interest to other communities and society in general, writes Dr Mullen, noting the importance of the issue to the military, aerospace industry, care for and wellbeing of the elderly and the bedridden and those who suffer from conditions involving the loss of autonomy, including ageing, muscle disorders and related disabilities).

Share and Tweet This Story

See the article here:
Why Detraining Is At The Heart Of The Swimming Playbook In Covid-19 Season 2020 - Swimming World Magazine

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global COVID-19 Impact on Male Breast Cancer Treatment market. It informs readers about key trends and opportunities in the global COVID-19 Impact on Male Breast Cancer Treatment market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global COVID-19 Impact on Male Breast Cancer Treatment market.

Key companies operating in the global COVID-19 Impact on Male Breast Cancer Treatment market include , Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, Accord Healthcare Male Breast Cancer Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1800824/covid-19-impact-on-global-male-breast-cancer-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global COVID-19 Impact on Male Breast Cancer Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global COVID-19 Impact on Male Breast Cancer Treatment Market Segment By Type:

, Medication, ChemOther

Global COVID-19 Impact on Male Breast Cancer Treatment Market Segment By Application:

, Hospitals, Clinics, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global COVID-19 Impact on Male Breast Cancer Treatment market.

Key companies operating in the global COVID-19 Impact on Male Breast Cancer Treatment market include , Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, Accord Healthcare Male Breast Cancer Treatment

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1800824/covid-19-impact-on-global-male-breast-cancer-treatment-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Male Breast Cancer Treatment Revenue1.4 Market Analysis by Type 1.4.1 Global Male Breast Cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Medication 1.4.3 Chemotherapy 1.4.4 Others1.5 Market by Application 1.5.1 Global Male Breast Cancer Treatment Market Share by Application: 2020 VS 2026 1.5.2 Hospitals 1.5.3 Clinics 1.5.4 Others1.6 Coronavirus Disease 2019 (Covid-19): Male Breast Cancer Treatment Industry Impact 1.6.1 How the Covid-19 is Affecting the Male Breast Cancer Treatment Industry 1.6.1.1 Male Breast Cancer Treatment Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Male Breast Cancer Treatment Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Male Breast Cancer Treatment Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Male Breast Cancer Treatment Market Perspective (2015-2026)2.2 Male Breast Cancer Treatment Growth Trends by Regions 2.2.1 Male Breast Cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Male Breast Cancer Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Male Breast Cancer Treatment Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Male Breast Cancer Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Male Breast Cancer Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Male Breast Cancer Treatment Players by Market Size 3.1.1 Global Top Male Breast Cancer Treatment Players by Revenue (2015-2020) 3.1.2 Global Male Breast Cancer Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Male Breast Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Male Breast Cancer Treatment Market Concentration Ratio 3.2.1 Global Male Breast Cancer Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Male Breast Cancer Treatment Revenue in 20193.3 Male Breast Cancer Treatment Key Players Head office and Area Served3.4 Key Players Male Breast Cancer Treatment Product Solution and Service3.5 Date of Enter into Male Breast Cancer Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Male Breast Cancer Treatment Historic Market Size by Type (2015-2020)4.2 Global Male Breast Cancer Treatment Forecasted Market Size by Type (2021-2026) 5 Male Breast Cancer Treatment Breakdown Data by Application (2015-2026)5.1 Global Male Breast Cancer Treatment Market Size by Application (2015-2020)5.2 Global Male Breast Cancer Treatment Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Male Breast Cancer Treatment Market Size (2015-2020)6.2 Male Breast Cancer Treatment Key Players in North America (2019-2020)6.3 North America Male Breast Cancer Treatment Market Size by Type (2015-2020)6.4 North America Male Breast Cancer Treatment Market Size by Application (2015-2020) 7 Europe7.1 Europe Male Breast Cancer Treatment Market Size (2015-2020)7.2 Male Breast Cancer Treatment Key Players in Europe (2019-2020)7.3 Europe Male Breast Cancer Treatment Market Size by Type (2015-2020)7.4 Europe Male Breast Cancer Treatment Market Size by Application (2015-2020) 8 China8.1 China Male Breast Cancer Treatment Market Size (2015-2020)8.2 Male Breast Cancer Treatment Key Players in China (2019-2020)8.3 China Male Breast Cancer Treatment Market Size by Type (2015-2020)8.4 China Male Breast Cancer Treatment Market Size by Application (2015-2020) 9 Japan9.1 Japan Male Breast Cancer Treatment Market Size (2015-2020)9.2 Male Breast Cancer Treatment Key Players in Japan (2019-2020)9.3 Japan Male Breast Cancer Treatment Market Size by Type (2015-2020)9.4 Japan Male Breast Cancer Treatment Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Male Breast Cancer Treatment Market Size (2015-2020)10.2 Male Breast Cancer Treatment Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Male Breast Cancer Treatment Market Size by Type (2015-2020)10.4 Southeast Asia Male Breast Cancer Treatment Market Size by Application (2015-2020) 11 India11.1 India Male Breast Cancer Treatment Market Size (2015-2020)11.2 Male Breast Cancer Treatment Key Players in India (2019-2020)11.3 India Male Breast Cancer Treatment Market Size by Type (2015-2020)11.4 India Male Breast Cancer Treatment Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Male Breast Cancer Treatment Market Size (2015-2020)12.2 Male Breast Cancer Treatment Key Players in Central & South America (2019-2020)12.3 Central & South America Male Breast Cancer Treatment Market Size by Type (2015-2020)12.4 Central & South America Male Breast Cancer Treatment Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Pfizer 13.1.1 Pfizer Company Details 13.1.2 Pfizer Business Overview and Its Total Revenue 13.1.3 Pfizer Male Breast Cancer Treatment Introduction 13.1.4 Pfizer Revenue in Male Breast Cancer Treatment Business (2015-2020)) 13.1.5 Pfizer Recent Development13.2 Roche 13.2.1 Roche Company Details 13.2.2 Roche Business Overview and Its Total Revenue 13.2.3 Roche Male Breast Cancer Treatment Introduction 13.2.4 Roche Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.2.5 Roche Recent Development13.3 GlaxoSmithKline 13.3.1 GlaxoSmithKline Company Details 13.3.2 GlaxoSmithKline Business Overview and Its Total Revenue 13.3.3 GlaxoSmithKline Male Breast Cancer Treatment Introduction 13.3.4 GlaxoSmithKline Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.3.5 GlaxoSmithKline Recent Development13.4 Sanofi 13.4.1 Sanofi Company Details 13.4.2 Sanofi Business Overview and Its Total Revenue 13.4.3 Sanofi Male Breast Cancer Treatment Introduction 13.4.4 Sanofi Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.4.5 Sanofi Recent Development13.5 Novartis 13.5.1 Novartis Company Details 13.5.2 Novartis Business Overview and Its Total Revenue 13.5.3 Novartis Male Breast Cancer Treatment Introduction 13.5.4 Novartis Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.5.5 Novartis Recent Development13.6 Bayer 13.6.1 Bayer Company Details 13.6.2 Bayer Business Overview and Its Total Revenue 13.6.3 Bayer Male Breast Cancer Treatment Introduction 13.6.4 Bayer Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.6.5 Bayer Recent Development13.7 Bristol-Myers Squibb 13.7.1 Bristol-Myers Squibb Company Details 13.7.2 Bristol-Myers Squibb Business Overview and Its Total Revenue 13.7.3 Bristol-Myers Squibb Male Breast Cancer Treatment Introduction 13.7.4 Bristol-Myers Squibb Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.7.5 Bristol-Myers Squibb Recent Development13.8 Eli Lilly 13.8.1 Eli Lilly Company Details 13.8.2 Eli Lilly Business Overview and Its Total Revenue 13.8.3 Eli Lilly Male Breast Cancer Treatment Introduction 13.8.4 Eli Lilly Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.8.5 Eli Lilly Recent Development13.9 AstraZeneca 13.9.1 AstraZeneca Company Details 13.9.2 AstraZeneca Business Overview and Its Total Revenue 13.9.3 AstraZeneca Male Breast Cancer Treatment Introduction 13.9.4 AstraZeneca Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.9.5 AstraZeneca Recent Development13.10 Teva Pharmaceutical 13.10.1 Teva Pharmaceutical Company Details 13.10.2 Teva Pharmaceutical Business Overview and Its Total Revenue 13.10.3 Teva Pharmaceutical Male Breast Cancer Treatment Introduction 13.10.4 Teva Pharmaceutical Revenue in Male Breast Cancer Treatment Business (2015-2020) 13.10.5 Teva Pharmaceutical Recent Development13.11 Sun Pharmaceutical 10.11.1 Sun Pharmaceutical Company Details 10.11.2 Sun Pharmaceutical Business Overview and Its Total Revenue 10.11.3 Sun Pharmaceutical Male Breast Cancer Treatment Introduction 10.11.4 Sun Pharmaceutical Revenue in Male Breast Cancer Treatment Business (2015-2020) 10.11.5 Sun Pharmaceutical Recent Development13.12 BioNumerik Pharmaceuticals 10.12.1 BioNumerik Pharmaceuticals Company Details 10.12.2 BioNumerik Pharmaceuticals Business Overview and Its Total Revenue 10.12.3 BioNumerik Pharmaceuticals Male Breast Cancer Treatment Introduction 10.12.4 BioNumerik Pharmaceuticals Revenue in Male Breast Cancer Treatment Business (2015-2020) 10.12.5 BioNumerik Pharmaceuticals Recent Development13.13 Seattle Genetics 10.13.1 Seattle Genetics Company Details 10.13.2 Seattle Genetics Business Overview and Its Total Revenue 10.13.3 Seattle Genetics Male Breast Cancer Treatment Introduction 10.13.4 Seattle Genetics Revenue in Male Breast Cancer Treatment Business (2015-2020) 10.13.5 Seattle Genetics Recent Development13.14 Accord Healthcare 10.14.1 Accord Healthcare Company Details 10.14.2 Accord Healthcare Business Overview and Its Total Revenue 10.14.3 Accord Healthcare Male Breast Cancer Treatment Introduction 10.14.4 Accord Healthcare Revenue in Male Breast Cancer Treatment Business (2015-2020) 10.14.5 Accord Healthcare Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Original post:
COVID-19 Impact on Male Breast Cancer Treatment Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By...

"There are so many unanswered questions, so many puzzles we are yet to solve," she said.

Dr Bart should have been on a plane on Monday, bound for Harvard University and the Brigham and Women's Hospital in Massachusetts for her 10-month Fulbright exchange placement, collaborating with fellow bright minds to unravel the complexities of cardiac genetics.

The Fulbright Program is a highly coveted US foreign exchange scholarship program, aimed at increasing bi-national research collaboration, cultural understanding and the exchange of ideas.

The COVID-19 pandemic has waylaid Dr Bart's travel plans and diverted her attention to the effects of the virus on cardiac patients. But she is continuing her research into the genetic roots of cardiac disease, in particular cardiac amyloidosis, where abnormal protein deposits amyloid fibrils build up in heart tissue, causing heart failure.

Amyloid heart disease used to be a death sentence, Dr Bart said.

"By the time we see patients and diagnose them, it's often too late. We had no treatment we could offer these patients until very recently," she said. "Now that we have those treatments we have a clinical imperative to diagnose early [using genetic testing].

"We are on this cusp of a genetics and genomic revolution where patients can be offered treatment based on their individual genetic make-up," Dr Bart said. "It's hugely exciting".

Being on the cusp of scientific breakthroughs seems like a fitting spot for the expert mountaineer. Dr Bart and her mother, Cheryl Bart, were first mother-daughter team to summit Everest and complete the "Seven Summits" challenge climbing the highest mountains on each continent.

Loading

"I appreciate what it feel like to push your body to the extreme," she said.

"The thing about being in high altitudes, up about 8000 metres, you have to focus on the next step and breath. There's a mindfulness to that focus, and not worrying about the bigger problem. You have a plan in place and you just keep taking that next step."

It's an ethos she brings to her research in the male-dominated field. Women account for just 15 per cent of cardiologists in Australia.

"There is still a huge gender gap, and this is likely affecting outcomes in research," she said. "The fascinating thing about women's hearts is that they behave different to men's. The signs and symptoms are different. Women don't have that thumping elephant-on-the-chest pain. They have more subtle symptoms.

"It's imperative that we have more female specialists and we utilise our different ways of thinking. We need more people to think laterally and collaborate."

Associate Professor Anthony Schembri, chief executive officer at St Vincent's Hospital, described Dr Bart as "a compassionate specialist who cares deeply for each of her patients, at the same time as undertaking research from the bench to the bedside with the aim of achieving long-term improved outcomes in her field of cardiac genetics".

Loading

Victor Chang Cardiac Research Institute executive director Professor Jason Kovacic said Dr Bart was "one of the many inspiring women in science, a trailblazer, pushing the boundaries and paving the way for hopefully more women considering a career as a researcher".

"It is a great honour to be awarded a Fulbright scholarship, and it is a reflection of Dr Bart's dedication to be at the forefront of medical research and ensure that studies are not undertaken in isolation but rather in collaboration with global partners to truly make a difference for patients suffering from heart disease," he said.

Kate Aubusson is Health Editor of The Sydney Morning Herald.

View post:
Sydney cardiologist honoured with Fulbright scholarship - Sydney Morning Herald

COVID-19 Impact on Global Male Breast Cancer Treatment Market Size, Status and Forecast 2020-2026, Key Regions, Types and Application, By Players, Type, Application, Marketing Channel and Region

This report focuses on the COVID-19 Impact on Global Male Breast Cancer Treatment Market status, future forecast, growth opportunity, key market and key players. The study objectives are to present COVID-19 Impact on Global Male Breast Cancer Treatment Market development in United States, Europe and China.

In 2019, COVID-19 Impact on Global Male Breast Cancer Treatment Market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2020-2025.

The report also summarizes the various types of COVID-19 Impact on Global Male Breast Cancer Treatment Market. Factors that influence the market growth of particular product category type and market status for it. A detailed study of COVID-19 Impact on Global Male Breast Cancer Treatment Market has been done to understand the various applications of the products usage and features. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

Get sample copy of this[emailprotected] https://www.lexisbusinessinsights.com/request-sample-133783

Top Key Players: Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, and Accord Healthcare

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they COVID-19 Impact on Global Male Breast Cancer Treatment Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the key market trends impacting the growth of COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the challenges to market growth?

Who are the key vendors in COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the market opportunities and threats faced by the vendors in COVID-19 Impact on Global Male Breast Cancer Treatment Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia COVID-19 Impact on Global Male Breast Cancer Treatment Market;

3.) The North American COVID-19 Impact on Global Male Breast Cancer Treatment Market;

4.) The European COVID-19 Impact on Global Male Breast Cancer Treatment Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

COVID-19 Impact on Global Male Breast Cancer Treatment Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2026

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-133783

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

APAC: +91 9867799788

[emailprotected]

http://www.lexisbusinessinsights.com

See the original post here:
COVID-19 Impact on Global Male Breast Cancer Treatment Market Size, Status and Forecast 2020-2026,Top Key Players: Pfizer, Roche, GlaxoSmithKline,...